



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## JH-RE-06-d<sub>6</sub>

|                    |                                                                                              |
|--------------------|----------------------------------------------------------------------------------------------|
| Cat. No.:          | HY-126214S                                                                                   |
| Molecular Formula: | C <sub>20</sub> H <sub>10</sub> D <sub>6</sub> Cl <sub>3</sub> N <sub>3</sub> O <sub>4</sub> |
| Molecular Weight:  | 474.75                                                                                       |
| Target:            | DNA/RNA Synthesis                                                                            |
| Pathway:           | Cell Cycle/DNA Damage                                                                        |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis.    |



### BIOLOGICAL ACTIVITY

#### Description

JH-RE-06-d<sub>6</sub> is deuterium labeled JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC<sub>50</sub>=0.78 μM; K<sub>i</sub>=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy<sup>[1]</sup>.

### REFERENCES

[1]. Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019;178(1):152-159.e11.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA